Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares

Rhea-AI Filing Summary

Allogene Therapeutics reported a Form 144 notice for 47,763 shares of Common Stock related to the vesting of restricted stock units on 03/13/2026. The filing lists these shares as granted under the issuer's equity compensation plan and shows the transaction date as 03/13/2026.

Insights

Equity Compensation Specialist

Form 144 records RSU vesting and potential resale of 47,763 shares.

The filing documents the vesting of restricted stock units and lists 47,763 Common Shares with the vesting/transaction date 03/13/2026. It also notes the grant was made under the issuer's equity compensation plan.

Timing and method of any resale are not described in the excerpt; subsequent filings or broker notices would show whether sales were executed under Rule 144 or another distribution method.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	47763	117826.97	243777920	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/13/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc			47763	03/13/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Allogene (ALLO) Form 144 disclose?

The Form 144 discloses the vesting of 47,763 restricted stock units on 03/13/2026. It lists these shares as granted under the issuer's equity compensation plan and identifies them as Common Stock potentially subject to resale rules.

Does the Form 144 mean the shares were sold immediately?

Not necessarily. The filing records the vesting and intent to sell under Rule 144 for 47,763 shares on 03/13/2026, but it does not provide execution details or confirm completed sales or proceeds from any transactions.

Who issued the restricted stock units listed in the filing?

The restricted stock units were issued by Allogene Therapeutics, Inc. and are identified in the filing as granted under the company’s equity compensation plan, with the vesting/transaction date shown as 03/13/2026.

How many shares are involved in the RSU vesting for ALLO?

The disclosure lists 47,763 shares of Common Stock tied to the vesting of restricted stock units on 03/13/2026. That quantity appears in the filing’s securities-to-be-sold section and is linked to the equity compensation grant.

Where can I find confirmation of any actual resale for ALLO shares?

Confirmation of executed sales would appear in subsequent broker reports or resale filings. The Form 144 lists intent/availability for resale of 47,763 shares on 03/13/2026 but does not show trade execution or proceeds.